Authors :
Kajal; Dev Raj Sharma; Vinay Pandit; M.S. Ashawat
Volume/Issue :
Volume 7 - 2022, Issue 5 - May
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3944yTF
DOI :
https://doi.org/10.5281/zenodo.6605007
Abstract :
As people live longer, the prevalence of
osteoarthritis has increased, making it the most frequent
kind of arthritis. During osteoarthritis, tissue of cartilage
on articular joints corrodes, causing pain and sometimes
debilitating loss of function in patients. The most
significant risk factor for osteoarthritis is getting older.
Osteoarthritis, is the most common chronic joint illness,
and becomes common nowadays as people become older.
It disturbs the majority of people over 65 and is a main
musculoskeletal reason of reduced mobility in the
elderly. Because the particular molecular mechanisms
behind the degradation of cartilage matrix and the
development of OA are unknown, there are presently no
viable therapies to slow the advancement of OA or
prevent irreversible cartilage degradation other than
total joint replacement surgery. The major molecular
pathways involved in OA pathogenesis will be discussed
in this study, as well as new insights into prospective
molecular targets. Various Novel carrier are used to
enhancement of drug delivery to the site of action.
Keywords :
Osteoarthritis(OA),Aging, Cartilage,Distruction,Nanocarrier
As people live longer, the prevalence of
osteoarthritis has increased, making it the most frequent
kind of arthritis. During osteoarthritis, tissue of cartilage
on articular joints corrodes, causing pain and sometimes
debilitating loss of function in patients. The most
significant risk factor for osteoarthritis is getting older.
Osteoarthritis, is the most common chronic joint illness,
and becomes common nowadays as people become older.
It disturbs the majority of people over 65 and is a main
musculoskeletal reason of reduced mobility in the
elderly. Because the particular molecular mechanisms
behind the degradation of cartilage matrix and the
development of OA are unknown, there are presently no
viable therapies to slow the advancement of OA or
prevent irreversible cartilage degradation other than
total joint replacement surgery. The major molecular
pathways involved in OA pathogenesis will be discussed
in this study, as well as new insights into prospective
molecular targets. Various Novel carrier are used to
enhancement of drug delivery to the site of action.
Keywords :
Osteoarthritis(OA),Aging, Cartilage,Distruction,Nanocarrier
